Delcath Systems (DCTH) said Monday it has received US Food and Drug Administration clearance to begin patient enrollment for a phase 2 clinical trial evaluating Hepzato in combination with standard of care for liver-dominant metastatic breast cancer.
The trial will assess the safety and efficacy of this combination therapy, aiming to offer a new treatment option for patients with limited alternatives, the company said, adding that about 90 patients will be enrolled across more than 20 sites in the US and Europe, with enrollment starting in Q4.
The trial's primary endpoint, hepatic progression-free survival, is expected by the end of 2028, with overall survival results, a secondary endpoint, anticipated in 2029, Delcath said.
Shares of Delcath were down 1.7% in recent Monday trading.
Price: 11.90, Change: -0.21, Percent Change: -1.73
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。